From clinical markers to community support: The future of lupus treatment

Michael P. Madaio

Research output: Contribution to journalArticlepeer-review


Systemic lupus erythematosus (SLE) is a chronic autoimmune disease in which the immune system, for unknown reasons, becomes hyperactive and attacks normal tissue. SLE can affect any part of the body, but most often harms the joints, skin, lungs, blood vessels, kidneys cardiovascular and nervous systems. Dr Michael Madaio is a lead researcher in this area, seeking to improve the diagnosis and treatment of kidney disease in lupus patients. Dr Madaio was recently appointed the Section Chief of Nephrology and Kidney Transplantation in the Department of Medicine at Temple University School of Medicine, PA, USA. Previous to this he was a Professor at the University of Pennsylvania School of Medicine. Dr Madaio's main research area is the immunology of nephritis, in particular lupus nephritis and glomerular diseases. Here he discusses future directions in lupus diagnosis and treatment and the importance of providing support for lupus patients in the community.

Original languageEnglish (US)
Pages (from-to)247-250
Number of pages4
JournalFuture Rheumatology
Issue number3
StatePublished - Jun 2007
Externally publishedYes

ASJC Scopus subject areas

  • Rheumatology


Dive into the research topics of 'From clinical markers to community support: The future of lupus treatment'. Together they form a unique fingerprint.

Cite this